Articles related to CLINICAL TRIALS

A large-scale randomized controlled trial (n=1,504) demonstrates that medication abortion initiated before ultrasound confirmation of intrauterine pregnancy achieves a 95.2% complete abortion rate, statistically noninferior to standard delayed treatment protocols.

A landmark analysis shows that physiology-guided complete revascularization reduced adverse outcomes by approximately 25% compared to culprit-only strategy across both STEMI and NSTEMI patients.

In a phase 3 trial comparing belzutifan to everolimus for advanced renal-cell carcinoma, belzutifan demonstrated a significant improvement in progression-free survival at 18 months (24.0% vs. 8.3%, P=0.002) and objective response rate (21.9% vs. 3.5%, P<0.001).

In a phase 3 trial involving 103 pediatric patients with congenital adrenal hyperplasia, crinecerfont treatment resulted in a mean reduction of androstenedione levels by 197 ng/dL after 4 weeks, compared to an increase of 71 ng/dL in the placebo group.

In a phase 3 trial, oral sebetralstat demonstrated a median time to beginning of symptom relief of 1.61 hours for the 300 mg dose and 1.79 hours for the 600 mg dose, compared to 6.72 hours for placebo in hereditary angioedema attacks.

Apple oral immunotherapy allowed patients to tolerate an entire apple after just 39 days on average, with potential cross-tolerance to other Rosaceae fruits.